注册一亩三分地论坛,查看更多干货!
您需要 登录 才可以下载或查看附件。没有帐号?注册账号 
x
中生集团在周二宣布将在中东国家进行Covid-19疫苗的三期试验,该公司研发的的疫苗已在阿拉伯联合酋长国得到了监管部门的批准。这家总部位于北京的生物集团公司是中国第一家走向三期试验的疫苗开发商,也是全球众多疫苗研发公司中首批获得最后阶段人体试验资格的企业之一。由于中国有效控制疫情,目前境内处于感染阶段的病例数较少,而此实验需要成千上万的患者参与,中国企业显然无法在国内进行,不得不寻找人数感染较多的地方以完成最后阶段的人体试验,而阿联酋刚好合适。因为截至目前,阿联酋每天仍在增加数百例病例,总感染人数超过4.5万人。中生集团此前已经进行了I期和II期的试验,让两种疫苗对约2000人进行了测试,最后证实其中一种疫苗总体安全,另外一只疫苗安全性将在6月28日公布。此次在阿联酋进行的III期实验,中生集团的主要目是测试开发的两种针剂是否可以效对抗该病原体。
A Chinese state-owned vaccine developer secured regulatory approval to test its coronavirus shots in the United Arab Emirates, making it one of the first among a slew of global efforts to get the greenlight for the final stage of human trials. Beijing-based China National Biotec Group Co. was awarded approval on Tuesday to conduct Phase III trials for its Covid-19 vaccines in the Middle Eastern country. CNBG is the first Chinese vaccine developer to proceed toward a Phase III trial to test whether the two shots it developed are effective against the pathogen. Chinese companies have had to look for places with active virus outbreaks to complete the final stage of human testing, which requires thousands of people. The low number of cases in China has made it unfeasible for them to conduct such trials at home. The U.A.E. is still adding hundreds of cases a day, with a total of more than 45,000 infections. The two shots developed by CNBG have already been tested among some 2,000 people in phase I and II trials conducted in China. One of the vaccines has been found to be generally safe, while data from the other one will be revealed on June 28. CNBG is the first Chinese vaccine developer to proceed toward a Phase III trial to test whether the two shots it developed are effective against the pathogen. source
指尖新闻:高信噪比,一目了然
新冠疫情追踪 |